vs
ExlService Holdings, Inc.（EXLS）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
ExlService Holdings, Inc.的季度营收约是Prestige Consumer Healthcare Inc.的1.9倍（$542.6M vs $283.4M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 11.1%，领先5.4%），ExlService Holdings, Inc.同比增速更快（12.7% vs -2.4%），ExlService Holdings, Inc.自由现金流更多（$106.5M vs $75.3M），过去两年ExlService Holdings, Inc.的营收复合增速更高（11.5% vs 1.2%）
ExlService Holdings Inc.是全球知名的分析与数字解决方案服务商，服务覆盖保险、医疗健康、银行金融服务、媒体、零售等多个行业，总部位于纽约，在美国、欧洲、亚洲、拉美、澳大利亚、南非等地拥有超过5.4万名专业从业人员。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
EXLS vs PBH — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $542.6M | $283.4M |
| 净利润 | $60.2M | $46.7M |
| 毛利率 | 38.6% | 55.5% |
| 营业利润率 | 14.4% | 29.1% |
| 净利率 | 11.1% | 16.5% |
| 营收同比 | 12.7% | -2.4% |
| 净利润同比 | 18.9% | -23.5% |
| 每股收益（稀释后） | $0.38 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $542.6M | $283.4M | ||
| Q3 25 | $529.6M | $274.1M | ||
| Q2 25 | $514.5M | $249.5M | ||
| Q1 25 | $501.0M | $296.5M | ||
| Q4 24 | $481.4M | $290.3M | ||
| Q3 24 | $472.1M | $283.8M | ||
| Q2 24 | $448.4M | $267.1M | ||
| Q1 24 | $436.5M | $277.0M |
| Q4 25 | $60.2M | $46.7M | ||
| Q3 25 | $58.2M | $42.2M | ||
| Q2 25 | $66.1M | $47.5M | ||
| Q1 25 | $66.6M | $50.1M | ||
| Q4 24 | $50.7M | $61.0M | ||
| Q3 24 | $53.0M | $54.4M | ||
| Q2 24 | $45.8M | $49.1M | ||
| Q1 24 | $48.8M | $49.5M |
| Q4 25 | 38.6% | 55.5% | ||
| Q3 25 | 38.5% | 55.3% | ||
| Q2 25 | 37.7% | 56.2% | ||
| Q1 25 | 38.6% | 57.3% | ||
| Q4 24 | 38.1% | 55.5% | ||
| Q3 24 | 37.8% | 55.5% | ||
| Q2 24 | 37.1% | 54.7% | ||
| Q1 24 | 37.4% | 54.8% |
| Q4 25 | 14.4% | 29.1% | ||
| Q3 25 | 14.4% | 29.1% | ||
| Q2 25 | 15.8% | 28.8% | ||
| Q1 25 | 15.7% | 29.8% | ||
| Q4 24 | 14.8% | 31.7% | ||
| Q3 24 | 14.7% | 29.7% | ||
| Q2 24 | 13.7% | 27.0% | ||
| Q1 24 | 14.1% | 29.7% |
| Q4 25 | 11.1% | 16.5% | ||
| Q3 25 | 11.0% | 15.4% | ||
| Q2 25 | 12.8% | 19.0% | ||
| Q1 25 | 13.3% | 16.9% | ||
| Q4 24 | 10.5% | 21.0% | ||
| Q3 24 | 11.2% | 19.2% | ||
| Q2 24 | 10.2% | 18.4% | ||
| Q1 24 | 11.2% | 17.9% |
| Q4 25 | $0.38 | $0.97 | ||
| Q3 25 | $0.36 | $0.86 | ||
| Q2 25 | $0.40 | $0.95 | ||
| Q1 25 | $0.40 | $1.00 | ||
| Q4 24 | $0.31 | $1.22 | ||
| Q3 24 | $0.33 | $1.09 | ||
| Q2 24 | $0.28 | $0.98 | ||
| Q1 24 | $0.29 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $328.4M | $62.4M |
| 总债务越低越好 | $298.6M | $1.0B |
| 股东权益账面价值 | $912.7M | $1.8B |
| 总资产 | $1.7B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.33× | 0.56× |
8季度趋势，按日历期对齐
| Q4 25 | $328.4M | $62.4M | ||
| Q3 25 | $390.1M | $119.1M | ||
| Q2 25 | $353.3M | $139.5M | ||
| Q1 25 | $331.4M | $97.9M | ||
| Q4 24 | $340.6M | $50.9M | ||
| Q3 24 | $325.8M | $51.5M | ||
| Q2 24 | $276.1M | $34.3M | ||
| Q1 24 | $246.2M | $46.5M |
| Q4 25 | $298.6M | $1.0B | ||
| Q3 25 | $354.8M | $993.1M | ||
| Q2 25 | $260.0M | $992.7M | ||
| Q1 25 | $307.3M | $992.4M | ||
| Q4 24 | $288.5M | $992.0M | ||
| Q3 24 | $344.7M | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $912.7M | $1.8B | ||
| Q3 25 | $952.4M | $1.8B | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $1.0B | $1.8B | ||
| Q4 24 | $929.9M | $1.8B | ||
| Q3 24 | $907.6M | $1.7B | ||
| Q2 24 | $852.6M | $1.7B | ||
| Q1 24 | $803.3M | $1.7B |
| Q4 25 | $1.7B | $3.5B | ||
| Q3 25 | $1.7B | $3.4B | ||
| Q2 25 | $1.7B | $3.4B | ||
| Q1 25 | $1.7B | $3.4B | ||
| Q4 24 | $1.6B | $3.3B | ||
| Q3 24 | $1.6B | $3.3B | ||
| Q2 24 | $1.5B | $3.3B | ||
| Q1 24 | $1.4B | $3.3B |
| Q4 25 | 0.33× | 0.56× | ||
| Q3 25 | 0.37× | 0.54× | ||
| Q2 25 | 0.25× | 0.54× | ||
| Q1 25 | 0.30× | 0.54× | ||
| Q4 24 | 0.31× | 0.55× | ||
| Q3 24 | 0.38× | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | $106.5M | $75.3M |
| 自由现金流率自由现金流/营收 | 19.6% | 26.6% |
| 资本支出强度资本支出/营收 | 2.0% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.95× | 1.68× |
| 过去12个月自由现金流最近4个季度 | $298.1M | $267.2M |
8季度趋势，按日历期对齐
| Q4 25 | $117.4M | $78.3M | ||
| Q3 25 | $120.7M | $57.5M | ||
| Q2 25 | $109.4M | $79.0M | ||
| Q1 25 | $3.2M | $61.8M | ||
| Q4 24 | $105.3M | $65.1M | ||
| Q3 24 | $110.1M | $69.8M | ||
| Q2 24 | $74.9M | $54.8M | ||
| Q1 24 | $-21.9M | $66.9M |
| Q4 25 | $106.5M | $75.3M | ||
| Q3 25 | $106.4M | $55.4M | ||
| Q2 25 | $95.0M | $78.2M | ||
| Q1 25 | $-9.7M | $58.4M | ||
| Q4 24 | $95.3M | $63.5M | ||
| Q3 24 | $97.3M | $67.8M | ||
| Q2 24 | $62.8M | $53.6M | ||
| Q1 24 | $-33.1M | $63.8M |
| Q4 25 | 19.6% | 26.6% | ||
| Q3 25 | 20.1% | 20.2% | ||
| Q2 25 | 18.5% | 31.3% | ||
| Q1 25 | -1.9% | 19.7% | ||
| Q4 24 | 19.8% | 21.9% | ||
| Q3 24 | 20.6% | 23.9% | ||
| Q2 24 | 14.0% | 20.1% | ||
| Q1 24 | -7.6% | 23.0% |
| Q4 25 | 2.0% | 1.1% | ||
| Q3 25 | 2.7% | 0.8% | ||
| Q2 25 | 2.8% | 0.3% | ||
| Q1 25 | 2.6% | 1.2% | ||
| Q4 24 | 2.1% | 0.5% | ||
| Q3 24 | 2.7% | 0.7% | ||
| Q2 24 | 2.7% | 0.4% | ||
| Q1 24 | 2.6% | 1.1% |
| Q4 25 | 1.95× | 1.68× | ||
| Q3 25 | 2.08× | 1.36× | ||
| Q2 25 | 1.66× | 1.66× | ||
| Q1 25 | 0.05× | 1.23× | ||
| Q4 24 | 2.08× | 1.07× | ||
| Q3 24 | 2.08× | 1.28× | ||
| Q2 24 | 1.63× | 1.12× | ||
| Q1 24 | -0.45× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
